Nuplazid (pimavanserin) is well-tolerated and can lead to clinical improvement in people with Parkinson’s disease psychosis (PDP), according to the results of studies into its real-life use. Acadia will present these data at the 2018 American Academy of Neurology ANN Annual Meeting, taking place in Los Angeles from…
Global Kinetics Corporation has obtained $350,000 in foundation funding to conduct a global clinical trial of its wearable device for recording Parkinson’s patients’ movement information. In addition to tracking movement, the watch-like Personal KinetiGraph reminds patients to take their medication and records when they do. The…
Parkinson’s treatment candidate BIIB054 was well-tolerated and had a favorable pharmacological profile in preliminary Phase 1 clinical results. Biogen will present those results at the 2018 American Academy of Neurology ANN Annual Meeting in Los Angeles, California, April 21-27. Parkinson’s News Today will be covering the conference. The presentation “Randomized, Double-Blind,…
Human neural stem cells show promise as therapy for Parkinson’s disease, according to six-month interim results of Phase 1 trial. The therapy’s developer, International Stem Cell’s Corporation subsidiary Cyto Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be…
The pharmaceutical company Bial has created a video of Parkinson’s patients dancing during daily tasks to inspire others to rise up to challenges and let more people know about the disease. It has been posted on Bial’s and a number of other organizations’ websites. You can also find it…
The U.S. Food and Drug Administration is keeping close watch on the use of Nuplazid (pimavanserin) by Parkinson’s patients with disease-related psychosis, but at present sees no reasons to change the existing warnings placed on the medication — sold by Acadia Pharmaceuticals — when first approved. The FDA stated…
Inbrija reduces Parkinson’s symptoms when standard treatments wear off, and decreases the length of these off periods, a Phase 3 clinical trial shows. The therapy’s developer, Acorda Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be covering…
A startup developing a device for more affordable and efficient magnetic resonance imaging (MRI) scans was recently awarded a Small Business Technology Transfer (STTR) grant from the National Institutes of Health. MR-Link, a technology company affiliated with Purdue University, will receive $228,325 to develop the device. Researchers say it will…
The Parkinson Voice Project will be live-streaming an expert’s presentation on the misconceptions about Parkinson’s disease on April 14. Columbia University Professor Stanley Fahn’s presentation will start at 10 a.m. U.S. Central Daylight time. It will be followed by speech therapy award presentations and a choir performance. The title of the…
Long waits for diagnosis, limited access to specialized treatments and services, and out-of-pocket healthcare costs are among key concerns of Parkinson’s patients, caregivers, and medical-service providers, according to a Parkinson Canada survey. The organization created the 30-minute online survey to better understand the challenges that patients, caregivers, and…
Get regular updates to your inbox.
